Delving into the Latest Updates on Axicabtagene Ciloleucel with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

anti-CD19 CAR T cell therapy, 抗CD19 CAR T细胞, 益基利仑赛

+ [11]

Target

CD19

Action

modulators

Mechanism

CD19 modulators(B-lymphocyte antigen CD19 modulators)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Primary mediastinal large B-cell lymphoma refractoryHigh grade B-cell lymphomaRecurrent Follicular Lymphoma+ [24]

Inactive Indication

B-cell lymphoma recurrentB-cell lymphoma refractoryRefractory Aggressive Non-Hodgkin Lymphoma

Originator Organization

Kite Pharma, Inc.

Active Organization

Fosun Kite Biotechnology Co., Ltd.

Kite Pharma, Inc.

Gilead Sciences, Inc.

+ [6]

Inactive Organization-

License Organization

Cencora, Inc.

Kite Pharma, Inc.

Kiniksa Pharmaceuticals Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (18 Oct 2017),

B-Cell LymphomaDiffuse Large B-Cell LymphomaFollicular Lymphoma+ [2]

RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Regenerative Medicine Advanced Therapy (United States), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Sequence Code 9718ScFv

Sequence Code 170963ScFv

Sequence Code 13042446CAR construct

The goal of this clinical trial is to evaluate the efficacy and safety of early secondary infusion of CD19 CAR T-cell therapy in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), guided by ctDNA monitoring. The main questions it aims to answer are:
1. Efficacy: Does early secondary CAR-T infusion improve the 3-month complete remission (CR) rate and long-term survival outcomes (e.g., 1-year PFS, OS)?
2. Safety: What are the adverse events associated with secondary CAR-T infusion, such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), and infections?
This is a single-arm, single-center, prospective study. All participants will receive:
* Leukapheresis to collect T cells for CAR-T manufacturing.
* Preconditioning chemotherapy (fludarabine and cyclophosphamide) to prepare the body for CAR-T infusion.
* Two CD19 CAR-T infusions: The first infusion (2×10⁶ cells/kg) followed by a second infusion (same dose) if ctDNA remains positive when PET/CT shows CR or PET/CT shows PR within 60 days post-first infusion.
Participants will undergo:
* Frequent hospital monitoring for ≥14 days post-infusion to manage potential toxicities.
* Regular follow-ups (e.g., blood tests, ctDNA analysis, PET/CT scans) at scheduled intervals up to 12 months.
* Continuous safety assessments, including CRS grading, neurological evaluations, and infection monitoring.

Start Date01 Feb 2027

Sponsor / Collaborator-

NCT07763210

/ RecruitingPhase 2IIT

A Phase 2 Trial of Early Enhanced Interventions to Prevent ICANS After CD19 CAR T Therapy in Patients With Non-Hodgkin Lymphoma: Lazarus Trial

The goal of this clinical trial is to reduce the duration of ICANS and incidence of G3 or great ICANS in participants who receive axi-cel. The main questions the study aims to answer are: Efficacy of IT therapy to reduce high-grade ICANS in participants who receive axi-cel in NHL compared to historical experience.
This phase II trial tests how well giving intrathecal (IT) cytarabine and hydrocortisone works for the early treatment of immune effector cell associated neurotoxicity syndrome (ICANS) in patients undergoing chimeric antigen response (CAR) t cell therapy for the treatment of non Hodgkin Lymphoma that has come back after a period of improvement (recurrent) or that has not responded o previous treatment (refractory). CAR T-cell therapy can sometimes cause an overactive immune response and inflammation. This can cause a side effect called ICANS that affects the rain and may lead to symptoms such as confusion, difficulty speaking, or other neurological problems. Giving cytarabine and hydrocortisone directly into the fluid around the brain and spinal cord (called intrathecal treatment) may help lower the body's immune response and reduce inflammation. Giving IT cytarabine and hydrocortisone may be effective for early treatment of CANS in patients undergoing CAR T cell therapy for relapsed or refractory non Hodgkin Lymphoma.

Start Date25 Sep 2026

Sponsor / Collaborator

The Vanderbilt-Ingram Cancer Center

[+1]

NCT07725406

/ Not yet recruitingPhase 1IIT

A Phase Ib, Dose-Escalation Study of Augmented Lymphodepletion and CAR T-cell Priming With Low-dose Total Body Irradiation in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphomas and Multiple Myeloma Receiving Treatment With Commercial CD19 or BCMA-directed CAR T-cell Therapies

This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make the immune system more active in fighting cancer by increasing the display of antigens and activating pathways that lead to cell death, including death receptors like FAS and TRAIL2. This approach is expected to help the CAR T cells grow and last longer, leading to stronger anti-tumor effects and more cancer cell deaths. Participants will receive LDTBI treatment before their CAR T cell therapy and will be followed up for 2 years.

Start Date01 Aug 2026

Sponsor / Collaborator

Weill Medical College of Cornell University

100 Clinical Results associated with Axicabtagene Ciloleucel

Login to view more data

100 Translational Medicine associated with Axicabtagene Ciloleucel

Login to view more data

100 Patents (Medical) associated with Axicabtagene Ciloleucel

Login to view more data

632

Literatures (Medical) associated with Axicabtagene Ciloleucel

01 Oct 2026·CLINICAL PHARMACOLOGY & THERAPEUTICS

Model‐Based Analysis with Mechanistic Insights to CAR ‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Article

Author: Ruiz‐Garcia, Ana ; Mc Laughlin, Anna M. ; Shen, Rhine ; Bergstrand, Martin ; Filosto, Simone

Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation. This limits its use for simulations of scenarios beyond the observed data. This work presents a mechanism‐based population PK framework that aims to bridge existing empirical and mechanistic CAR‐T‐cell modeling approaches. The model was developed using a clinical database of 473 patients with various relapsed or refractory lymphomas (large B cell, follicular, marginal zone, or mantle cell) receiving axicabtagene ciloleucel or brexucabtagene autoleucel. The framework incorporates two CAR‐T‐cell compartments alongside a latent kinetic‐pharmacodynamic tumor compartment, utilizing a continuous, mechanistically‐driven approach to characterize the observed PK profiles. A covariate search identified five significant covariates impacting PK ( P < 0.001). Among these, only product type/mantle cell lymphoma (MCL) disease type was deemed to have clinically relevant effects on exposure. Despite its mechanistic basis, the model remains parsimonious, requiring only seven structural parameters, and no additional data beyond post‐infusion CAR‐T‐cell peripheral blood concentrations and covariate information routinely collected in clinical trials. With its mechanistic foundation but parsimonious structure, this model balances data‐driven practicality with the integration of underlying biological processes. Its ability to identify relevant covariates could make it a valuable tool in supporting drug development decisions.

01 Oct 2026·SUPPORTIVE CARE IN CANCER

Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel

Article

Author: Khimani, Farhad ; Snider, Julia Thornton ; Hoogland, Aasha I ; Small, Brent J ; Li, Xiaoyin ; Pinilla-Ibarz, Javier ; Logue, Jennifer ; Liu, Hien D ; Booth-Jones, Margaret ; Rodriguez, Yvelise ; Mirza, Abu-Sayeef ; Lazaryan, Aleksandr ; Welniak, Taylor ; Locke, Frederick L ; Nishihori, Taiga ; Chavez, Julio C ; Wade, Sally W ; Jain, Michael D ; Jim, Heather S L ; Hu, Bihe ; Shah, Bijal D ; Irizarry-Arroyo, Nathaly ; Huang, Jeffrey ; Pidala, Joseph A ; Oswald, Laura B

Chimeric antigen receptor (CAR) T-cell therapy, including axicabtagene ciloleucel (axi-cel), is efficacious for older patients. However, patients aged 65 + are at risk for more severe neurotoxicity after infusion than younger patients, and post-infusion cognitive outcomes in older patients are unknown. This study assessed changes in objective neurocognitive performance in patients age 65 + compared to those younger than 65 in the first year after axi-cel and examined clinical factors influencing these changes. In patients with large B-cell lymphoma, neuropsychological assessments were conducted prior to initiation of axi-cel and at 30, 90, and 360 days after infusion. Mixed effects models were used to investigate age differences in changes in overall cognition (e.g., total neuropsychological performance [TNP]) and specific domains (i.e., attention, executive function, verbal ability, immediate and delayed memory, and visuospatial abilities). Among 155 participants (63% male, 90% White), older adults (n = 69) were more likely than younger adults (48% vs. 34%, p < 0.05) to demonstrate overall neurocognitive impairment before infusion. However, older adults demonstrated greater recovery of cognitive abilities (e.g., immediate verbal memory and delayed memory) over time (ps < 0.01). These results suggest that CAR T-cell therapy may have a less detrimental impact on neurocognitive performance in older patients compared to younger patients.

22 Sep 2026·Blood Advances

Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

Article

Author: Maziarz, Richard T. ; Seshan, Venkatraman ; Brower, Jamie ; Manu, Gurusidda ; Bishop, Michael R. ; Perales, Miguel-Angel ; Wudhikarn, Kitsada ; Riedell, Peter A. ; Schuster, Stephen J. ; Ahmed, Sairah ; Bachanova, Veronika ; Porter, David L. ; McGuirk, Joseph P. ; Bromberg, Maria ; Oluwole, Olalekan O. ; Dahi, Parastoo B.

Abstract:

Late cytopenia (≥30 days after chimeric antigen receptor [CAR] T-cell therapy) is a significant complication after CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). However, available data remain limited and heterogeneous. In this retrospective multicenter study, we evaluated the incidence, patterns, risk factors, and impact of late cytopenia in patients treated with CD19 CAR T cells. A total of 444 patients with R/R LBCL treated at 8 academic centers within the Cell Therapy Consortium between April 2016 and May 2023 were included. After excluding patients with relapse, new treatment, death or lost to follow-up, grade ≥3 cytopenias were observed in 47%, 34%, 19%, 21%, and 11% of patients with available data at 1, 2, 3, 6, and 12 months after infusion. Among 307 patients with complete hematologic data, neutropenia consistent with late immune effector cell-associated hematotoxicity was identified in 103 patients (33.6%) between days 30 and 100. Multivariable analysis identified a high CAR-HEMATOTOX score (≥2) as a predictor of cytopenia at 3 months, whereas receipt of bridging chemotherapy and axicabtagene ciloleucel was associated with cytopenia at 6 months after CAR T-cell therapy. The presence of late cytopenia was associated with a higher 1-year nonrelapse mortality (11% vs 4.4%; P = .038), worse 2-year progression-free survival (38% vs 67%; P = .035), and worse 2-year overall survival (60% vs 76%; P = .016). In conclusion, late cytopenia is a common and clinically meaningful toxicity after CD19 CAR T-cell therapy. Recognition of risk factors and consistent monitoring are essential for optimizing post–CAR T-cell therapy care and reducing treatment-related mortality.

528

News (Medical) associated with Axicabtagene Ciloleucel

07 Oct 2026

·www.pharmaceutical-technology.com

CAR-T specialist Caribou culls pipeline and seeks exit deal

In a statement on LinkedIn, CEO Rachel Haurwitz said: “Caribou’s story has taken a heartbreaking turn.” Credit: Nanzeeba/Shutterstock.com. Caribou Biosciences, a biotech developing off-the-shelf cell therapies for blood cancers, said it will discontinue its pipeline and lay off employees – a move that reflects shifting investor appetite towards in vivo approaches. Caribou is shelving further development activities for its two allogeneic CAR-T cell therapy programmes, vispa-cel for the treatment of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma and CB-011 for the treatment of R/R multiple myeloma. In line with the pipeline winddown, the company is implementing reductions to its workforce and initiating cost-cutting measures. As of February 2026, 97 people worked at the company full-time. While not disclosing how many employees will be cut, Caribou said the reductions would be “substantial”. The biotech’s board is now seeking exit routes, including a merger, acquisition, business combination, or other deals that involve Caribou in its entirety or a transaction of assets. In a statement on LinkedIn, CEO Rachel Haurwitz said: “Caribou’s story has taken a heartbreaking turn. This decision is not a loss of belief in our science, our clinical data, or what these programmes could mean for patients. It reflects the difficult reality that the current financing environment for allogeneic CAR-T cell therapies has made it impossible to secure the capital required to responsibly advance them.” CAR T-cell therapy is a personalised type of immunotherapy that genetically reprogrammes a patient’s own white blood cells to identify and destroy cancer cells. Caribou’s approach takes conventional ex-vivo CAR-T and uses CRISPR genome editing to turn donor T cells into a standardised, “off-the-shelf” product. There is a plethora of approved CAR-T products, with Gilead’s Yescarta (axicabtagene ciloleucel) and Johnson & Johnson’s (J&J) Carvykti (ciltacabtagene autoleucel) the dominant drugs in oncology. However, in vivo CAR-T is starting to dominate R&D activities because it eliminates the need for expensive and convoluted manufacturing. Big pharma companies are starting to favour this approach for pipeline strategies, too. J&J, for example, inked a collaboration and potential buyout agreement with in vivo CAR-T specialist Sail Biomedicines worth up to $3.505bn in July 2026. Eli Lilly, AstraZeneca, and Moderna have all also set targets on the in vivo CAR-T space. For Caribou, the business wind-down marks a strong contrast to when it burst onto the biotech scene with so much promise. It was co-founded by Jennifer Doudna, who won the 2020 Nobel Prize in Chemistry alongside Emmanuelle Charpentier for their development of CRISPR-Cas9 genome editing. The biotech went on to have a successful $350m IPO in the US and even received financial backing from Pfizer and AbbVie. Haurwitz remained steadfast in the positive evidence supporting the company’s clinical programmes, saying: “These are not merely scientific concepts. These product candidates are therapies that have already made a difference in patients’ lives and could help many more. “As our board considers potential paths forward for the company and its assets, we hope there may be an opportunity for these off-the-shelf CAR-T cell therapies to be advanced by other organisations with the resources, capabilities, and commitment required.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

ImmunotherapyAcquisitionCell TherapyIPO

17 Sep 2026

·www.fiercepharma.com

Roche’s Lunsumio delivers positive confirmatory trial readout in follicular lymphoma

Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary endpoint in earlier-line follicular lymphoma. Without sharing any specific data, Roche and its subsidiary Genentech said Lunsumio’s combination with lenalidomide (Revlimid) demonstrated a statistically and clinically meaningful improvement in progression-free survival against rituximab (Rituxan) plus lenalidomide, known as R2, in the phase 3 Celestimo study. The trial enrolled follicular lymphoma (FL) patients who have received at least one prior line of treatment, and it serves as the confirmatory study required to convert Lunsumio’s existing accelerated approval as a monotherapy in third-line FL into a full approval, while also potentially moving the drug earlier into the second-line setting. Besides the positive PFS readout, Roche said overall survival data were immature but did not offer any further description. No new safety signals were identified beyond the known profile of each drug, the company added. Detailed data could help doctors and industry watchers understand the Lunsumio doublet’s position against Incyte’s Monjuvi and AbbVie and Genmab’s Epkinly , both of which won FDA approvals for second-line FL last year in three-drug regimens with R2. An in-class competitor to Lunsumio, Epkinly, used on top of R2, reduced second-line-plus patients’ risk of disease progression or death by 79% versus R2 alone, the phase 3 Epcore FL-1 trial showed. For its part, the addition of Monjuvi to R2 improved PFS 57% among second-line-plus patients in the phase 3 inMind trial. Both Lunsumio and Epkinly are CD20xCD3 T-cell engagers, while Monjuvi is an anti-CD19 antibody. The new Celestimo results “indicate that a two-drug outpatient Lunsumio regimen may offer these patients an effective new option earlier in their treatment journey,” Levi Garraway, M.D., Ph.D., Roche’s chief medical officer and head of global product development, said in a statement. In addition to the three antibody drugs, Gilead Sciences’ CD19 CAR-T, Yescarta, is being tested in the phase 3 Zuma-22 trial in second-line-plus FL. At the same time, BeOne Medicines is combining its small-molecule BTK inhibitor Brukinsa with Roche’s CD20 antibody Gazyva in the phase 3 Mahogany trial in previously treated FL and marginal zone lymphoma. Roche is targeting its CD20xCD3 portfolio across B-cell malignancies. The Swiss pharma’s combination of Lunsumio and its antibody-drug conjugate Polivy is awaiting an FDA decision in second-line diffuse-large B-cell lymphoma (DLBCL) by Feb. 9, 2027. Meanwhile, all eyes are on an upcoming readout from Roche’s Skyglo trial for the company’s other CD20xCD3 bispecific, Columvi, in first-line DLBCL. Lunsumio was also recently moved outside blood cancers and into a phase 1 systemic lupus erythematosus trial.

Phase 3ADCClinical ResultDrug ApprovalPhase 1

17 Aug 2026

·allsci.com

J&J hands C-CAR039 back to AbelZeta amid pivot toward in vivo CAR-T

Johnson & Johnson's Janssen Biotech has returned global rights to Maryland-based AbelZeta Pharma's anti-CD19/CD20 bispecific CAR-T cell therapy prizloncabtagene autoleucel (C-CAR039), unwinding a 2023 licensing deal under which Janssen paid USD 245 million upfront for rights to C-CAR039 and a second CAR-T asset outside Greater China. AbelZeta has since received US FDA clearance of an investigational new drug (IND) application to advance C-CAR039 in US trials for relapsed or refractory (r/r) large B-cell lymphoma (LBCL). The July 2026 rights return restores to AbelZeta development, regulatory, manufacturing, commercialization, and out-licensing control of C-CAR039 globally. Financial terms were not disclosed. AbelZeta said it is working with the US FDA to finalize protocols for two US populations: third-line or later LBCL patients previously treated with CAR-T and second-line CAR-T-naive patients. The asset returns with a relatively mature clinical dataset. Long-term results presented at the European Society for Blood and Marrow Transplantation in March 2026 covered 48 patients with r/r B-cell non-Hodgkin lymphoma (B-NHL). AbelZeta reported an overall response rate (ORR) of 91.5%, a complete response (CR) rate of 85.1%, and median progression-free survival of 60.1 months at a median follow-up of 53.9 months. A registrational Phase II study in CAR-T-naive r/r LBCL remains ongoing in China. Janssen previously revealed it was ending development of C-CAR-039 (also known as JNJ-4496) in May this year. C-CAR039 targets CD19 and CD20 simultaneously, an architecture intended to reduce antigen escape following CAR-T treatment. Loss or downregulation of target antigen is one resistance mechanism associated with single-target CD19 CAR-T therapies including axicabtagene ciloleucel and tisagenlecleucel. J&J's decision to hand the program back comes as the company makes a much larger commitment to next-generation in vivo CAR-T. Later in July, J&J agreed to USD 785 million in initial payments to Sail Biomedicines, including a USD 465 million equity investment, to develop in vivo CAR-T therapies for immune-mediated diseases. The agreement also includes up to USD 140 million in development-related contingent payments and gives J&J an option to acquire Sail for USD 2.58 billion. The transactions involve different indications and development strategies and J&J has not linked the two decisions. Taken together, however, they highlight a shift in where the company is deploying new cell therapy capital: away from at least one externally licensed ex vivo autologous CAR-T oncology program while making a substantial investment in technology designed to generate CAR-T cells directly inside the patient. For AbelZeta, the return provides full control of a clinical-stage asset just as it enters US development. The company has also attracted recent interest elsewhere in its CAR-T pipeline. In January 2026, AstraZeneca agreed to acquire AbelZeta's remaining China rights to GPC3-targeted C-CAR031, giving AstraZeneca sole global development and commercialization rights to the asset. In July, AbelZeta's CD20/BCMA bispecific C-CAR168 received EMA PRIME designation for lupus nephritis and systemic lupus erythematosus and US FDA clearance for a registrational Phase II trial in refractory lupus nephritis. One question remains over the second asset covered by the original Janssen relationship. A December 2023 amendment gave Janssen an option to obtain exclusive China commercialization rights to C-CAR039 and C-CAR066. AbelZeta's latest disclosure addresses the return of C-CAR039 but does not clarify the current status of C-CAR066 or the earlier China option. The return also comes amid a broader revaluation of cell therapy partnering. Large pharmaceutical companies have committed billions of dollars to in vivo CAR-T platforms during 2025–2026, reflecting interest in approaches that could eliminate the complex ex vivo manufacturing and treatment pathway required for conventional autologous CAR-T. For AbelZeta, the immediate question is whether the long-term Chinese clinical results for C-CAR039 can translate into competitive efficacy in US LBCL populations, including patients who have already failed a previous CAR-T therapy. Access the AllSci platform to explore the science behind the news. Spot something wrong? Report an issue with this article

Cell TherapyPhase 2ImmunotherapyClinical ResultLicense out/in

100 Deals associated with Axicabtagene Ciloleucel

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11144	-	L01	DB13915

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Primary mediastinal large B-cell lymphoma refractory	South Korea	Gilead Sciences Korea Ltd.	13 Aug 2025
High grade B-cell lymphoma	Canada	Gilead Sciences Canada, Inc.	13 Feb 2019
Recurrent Follicular Lymphoma	European Union	Kite Pharma EU BV	23 Aug 2018
Recurrent Follicular Lymphoma	Iceland	Kite Pharma EU BV	23 Aug 2018
Recurrent Follicular Lymphoma	Liechtenstein	Kite Pharma EU BV	23 Aug 2018
Recurrent Follicular Lymphoma	Norway	Kite Pharma EU BV	23 Aug 2018
Refractory Follicular Lymphoma	European Union	Kite Pharma EU BV	23 Aug 2018
Refractory Follicular Lymphoma	Iceland	Kite Pharma EU BV	23 Aug 2018
Refractory Follicular Lymphoma	Liechtenstein	Kite Pharma EU BV	23 Aug 2018
Refractory Follicular Lymphoma	Norway	Kite Pharma EU BV	23 Aug 2018
B-Cell Lymphoma	United States	Kite Pharma, Inc.	18 Oct 2017
Diffuse Large B-Cell Lymphoma	United States	Kite Pharma, Inc.	18 Oct 2017
Follicular Lymphoma	United States	Kite Pharma, Inc.	18 Oct 2017
Large B-cell lymphoma	United States	Kite Pharma, Inc.	18 Oct 2017
Mediastinal large B-cell lymphoma	United States	Kite Pharma, Inc.	18 Oct 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	United States	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Australia	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Austria	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Belgium	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Canada	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	France	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Germany	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Israel	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Italy	Kite Pharma, Inc.	25 Jan 2018
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Netherlands	Kite Pharma, Inc.	25 Jan 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Diffuse Large B-Cell Lymphoma	818	Axicabtagene ciloleucel (aged <70 years)	dpoilghshb(tgsjimytnf) = scjbnlgopa rgevaljvmx (qsdicartvu ) View more	Positive	29 May 2026
				Axicabtagene ciloleucel (aged ≥70 years)	dpoilghshb(tgsjimytnf) = xymocqspfq rgevaljvmx (qsdicartvu ) View more
ASCO2026	Not Applicable	Large B-cell lymphoma	1,311	Axicabtagene ciloleucel	crczohelkt(acmavmlmeu): HR = 0.86 (95.0% CI, 0.66 - 1.11) View more	Positive	29 May 2026
				Lisocabtagene maraleucel
ASCO2026	Not Applicable	Hematologic Neoplasms	1,117	Cilta-cel	oisrrfjbot(srqcncuoem) = oohwrrfetv tyubjrqpfd (bewetggpuq ) View more	Positive	29 May 2026
				Ide-cel	oisrrfjbot(srqcncuoem) = reiicfjtob tyubjrqpfd (bewetggpuq ) View more
ASCO2026	Not Applicable	Large B-cell lymphoma	1,446	Axicabtagene ciloleucel (axi-cel)	fktsnkeugq(lodnboeqcj) = xtejpvrhuu vwnnjbeznd (nsnqrmbfny ) View more	Positive	29 May 2026
ASGCT2026	Not Applicable	B-Cell Leukemia \| B-Cell Lymphoma \| Multiple Myeloma ... View more	469	Idecabtagene vicleucel (Abecma)	mfvibflzet(sshfmiizhb) = kzvuigggzx spdxodtgir (ewwaidkpjj ) View more	Positive	13 May 2026
				Lisocabtagene maraleucel (Breyanzi)	mfvibflzet(wqjrdxafee) = niauvhzvpb krxufhvcuc (mxkqwtidmg )
EHA2026	Not Applicable	Second line	40	Axi-cel (relapsed or refractory large B-cell lymphoma)	mdebynenhe(hkrlcncedk) = ulqcgmrilc deixnxfejj (tgsofykimt ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Large B-cell lymphoma Second line	311	Axicabtagene ciloleucel	rxjcfmsznz(pbjvcsqccj) = Cytokine release syndrome occurred in 95% of patients (grade 2-4: 37%; grade 3-4: 4%), and immune effector cell-associated neurotoxicity syndrome in 47% (grade 2-4: 26%; grade 3-4: 12.5%). nvqkptrrug (jqsszmdvjo ) View more	Positive	12 May 2026
				Standard chemoimmunotherapy (CIT) (transplant-eligible)
EHA2026	Not Applicable	Chronic Lymphocytic Leukemia	12	CAR2	dlfhkwjixv(agfgfkpsmn) = lkbaroxgsh btiskcdsfp (uzejaplpbo ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Large B-cell lymphoma	443	Axicabtagene ciloleucel	oamietannn(ipqhblwtsd) = oewbdmcvxv xkmbmbtdqb (vxzgrhsfzs ) View more	Positive	12 May 2026
				Lisocabtagene maraleucel	oamietannn(ipqhblwtsd) = ogslklxezm xkmbmbtdqb (vxzgrhsfzs ) View more
EHA2026	Not Applicable	B-Cell Lymphoma Consolidation	5	Axicabtagene ciloleucel (axi-cel)	wszbutnhrz(fskmcuqntr) = jgkvkxmfyl msramkwjwb (jckirvvpoc ) View more	Positive	12 May 2026